Current treatment of cutaneous squamous cancer and molecular strategies for its sensitization to new target-based drugs

Expert Opinion on Biological Therapy

Volumn 13, Issue 1, 2013, Pages 51-66

  Franco, Renato ^a   Nicoletti, Gianfranco ^b   Lombardi, Angela ^b   Di Domenico, Marina ^b   Botti, Gerardo ^a   Zito Marino, Federica ^a   Caraglia, Michele ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Bortezomib; BRAF; Cetuximab; Cis retinoic acid; CRAF; Cutaneous squamous cancer; Epidermal growth factor receptor; ErbB2; ErbB3; ErbB4; Erlotinib; Fas; Geldanamycin; Histopathological classification; Human papilloma virus; Interferon alpha; MEK inhibitors; P53; P63; Prognosis; Raf inhibitors; Raf kinase; Ras; Sun; Tipifarnib; Ultraviolet rays

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALPHA INTERFERON; ARF PROTEIN; BLEOMYCIN; CAPECITABINE; CETUXIMAB; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLOPHOSPHAMIDE; DABRAFENIB; DNA POLYMERASE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FAS ANTIGEN; FAS LIGAND; FLUOROURACIL; GEFITINIB; GROWTH FACTOR RECEPTOR; ISOTRETINOIN; METHOTREXATE; PROCARBAZINE; PROTEIN P53; PYRIMIDINE; RAS PROTEIN; VEMURAFENIB; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; BIOLOGICAL THERAPY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CELL SURVIVAL; DISEASE COURSE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SENSITIZATION; EPIGENETICS; GENE MUTATION; HUMAN; KERATOACANTHOMA; MOLECULARLY TARGETED THERAPY; MORTALITY; MULTIMODALITY CANCER THERAPY; ONCOGENE RAS; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; SKIN CARCINOGENESIS; SKIN CARCINOMA; SUN EXPOSURE; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; ULTRAVIOLET RADIATION;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; HUMANS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

HUMAN PAPILLOMAVIRUS;

EID: 84870924719     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.725720     Document Type: Review

References (100)

1. Bernstein SC, Lim KK, Brodland DG, Heidelberg KA. The many faces of squamous cell carcinoma. Dermatol Surg 1996;22:243-54
2. Gray DT, Suman VJ, Daniel Su WP, et al. Trends in the populationbased incidence of squamous cell carcinoma of the skin first diagnosed between 1984 and 1992. Arch Dermatol 1997;133:735-40
3. Lohmann CM, Solomon AR. Clinicopathologic variants of cutaneous squamous cell carcinoma. Adv Anat Pathol 2001;8:27-36
4. Cassarino DS, Linden KG, and Barr RJ. Cutaneous keratocyst arising independently of the nevoid basal cell carcinoma syndrome. Am J Dermatopathol 2005;27:177-8
5. Cassarino DS, De Rienzo DP, Barr RJ. Cutaneous squamous cell carcinoma: A comprehensive clinicopathologic classification-part two. J Cutan Pathol 2006;33:261-79
6. De Leeuw J, Van der Beek N, Neugebauer WD, et al. Fluorescence detection and diagnosis of non-Melanoma skin cancer at an early stage. Lasers Surg Med 2009;41:96-103
7. Miller D, Weinstock MA. Nonmelanoma skin cancer in the United States: Incidence. J Am Acad Dermatol 1994;30:774-8
8. Brash DE. UV mutagenic photoproducts in Escherichia coli and human cells: A molecular genetics perspective on human skin cancer. Photochem Photobiol 1988;48:59-66
9. Brash DE, Rudolph JA, Simon JA, et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA 1991;88:10124-8
10. Harris CC. Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996;88:1442-55
11. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wildtype p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 1992;89:7491-5
12. Zahn Q, Carrier F, Fornace AJ Jr. Induction of cellular p53 activity by DNA-damaging agents and growth arrest. Mol Cell Biol 1993;13:4242-50
13. Yonish-Roauch E, Reznitzky D, Lotem J, et al. Wild type p53 induces apoptosis of myeloid leukemic cells that is inhibited by IL-6. Nature 1991;352:345-7
14. Nelson WG, Kastan MB. DNA strand breaks: The DNA template alterations that trigger p53-dependent DNA damage response. Mol Cell Biol 1994;14:1815-23
15. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995;80:293-9
16. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 2001;7:683-94
17. Oda K, Arakawa H, Tanaka T, et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 2000;102:849-62
18. Hill LL, Ouhtit A, Loughlin SM, et al. Fas ligand: A sensor for DNA damage critical in skin cancer etiology. Science 1999;285:898-900
19. Nelson MA, Einspahr JG, Alberts DS, et al. Analysis of p53 gene in human precancerous actinic keratosis lesions and squamous cell cancers. Cancer Lett 1994;85:23-9
20. Campbell C, Quinn AG, Ro YS, et al. p53 mutations are common and early events that precede tumor invasion in squamous cell neoplasia of the skin. J Invest Dermatol 1993;100:746-8
21. Ziegler A, Jonason AS, Leffell DJ, et al. Sunburn and p53 in the onset of skin cancer. Nature 1994;372:773-6
22. Nakazawa H, English D, Randell PL, et al. UV and skin cancer: Ppecific p53 gene mutation in normal skin as a biologically relevant exposure measurement. Proc Natl Acad Sci USA 1994;91:360-4
23. Human epidermal cancer and accompanying precursors have identical p53 mutations different from p53 mutations in adjacent areas of clonally expanded non-neoplastic keratinocytes. Oncogene 1996;12:765-73
24. Jonason AS, Kunala S, Price GJ, et al. Frequent clones of p53-mutated keratinocytes in normal human skin. Proc Natl Acad Sci USA 1996;93:14025-9
25. Ananthaswamy HN, Loughlin SM, Cox P, et al. Sunlight and skin cancer: Inhibition of p53 mutations in UV-irradiated mouse skin by sunscreens. Nat Med 1997;3:510-14
26. Berg RJW, Van Kranen HJ, Rebel HG, et al. Early p53 alterations in mouse skin carcinogenesis by UVB radiation: Immunohistochemical detection of mutant p53 protein in clusters of preneoplastic epidermal cells. Proc Natl Acad Sci USA 1996;93:274-8
27. Remenyik E, Wikonkal NM, Zhang W, et al. Antigen-specific immunity does not mediate acute regression of UVB-induced p53-mutant clones. Oncogene 2003;22:6369-76
28. De Gruijl FR, Van der Leun JC. Development of skin tumors in hairless mice after discontinuation of ultraviolet irradiation. Cancer Res 1991;51:979-84
29. Candi E, Dinsdale D, Rufini A, et al. TAp63 and DeltaNp63 in cancer and epidermal development. Cell Cycle 2007;6:274-85
30. Duensing S, Munger K. Mechanisms of genomic instability in human cancer: Insights from studies with human papillomavirus oncoproteins. Int J Cancer 2004;109:157-62
31. De Villiers EM, Laverone D, McLaren K, Benton EC. Prevailing papillomavirus types in non-melanoma carcinomas of the skin in renal allograft recipients. Int J Cancer 1997;73:356-61
32. Dubina M, Goldenberg G. Viral-associated nonmelanoma skin cancers: A review. Am J Dermatopathol 2009;31:561-73
33. Harwood CA, Surentheran T, McGregor JM, et al. Human papilloma-virus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individuals. J Med Virol 2000;61:289-97
34. Meyer T, Arndt R, Nindl I, et al. Association of human papillomavirus infections with cutaneous tumors in immunosuppressed patients. Transpl Int 2003;16:146-53
35. Pfister H. Human papillomavirus and skin cancer. J Natl Cancer Inst Monogr 2003;8:52-6
36. Caldeira S, Zehbe I, Accardi R, et al. The E6 and E7 proteins of the cutaneous human papillomavirus type 38 display transforming properties. J Virol 2003;77:2195-206
37. Forslund O, Ly H, Reid C, Higgins G. A broad spectrum of human papillomavirus types is present in the skin of Australian patients with non-melanoma skin cancers and solar keratosis. Br J Dermatol 2003;149:64-73
38. Meyer T, Arndt R, Christophers E, et al. Importance of human papillomaviruses for the development of skin cancer. Cancer Detect Prev 2001;25:533-47
39. Ouhtit A, Gorny A, Muller HK, et al. Loss of Fas-ligand expression in mouse keratinocytes during UV carcinogenesis. Am J Pathol 2000;157:1975-81
40. Bachmann SA, Buechner M, Wernli S, et al. Erb Ultraviolet light downregulates CD95 ligand and TRAIL receptor expression facilitating actinic keratosis and squamous cell carcinoma formation. J Invest Dermatol 2001;117:59-66
41. Uribe P, Gonzalez S. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: Molecular bases for EGFR-targeted therapy. Pathol Res Pract 2011;207:337-42
42. Barbacid M. Ras genes. Ann Rev Biochem 1987;56:779-95
43. Bos JL. Ras oncogenes in human cancer: Review. Cancer Res 1989;49:4682-9
44. Ananthaswamy HN, Pierceall WE. Molecular mechanisms of ultraviolet radiation carcinogenesis. Photochem Photobiol 1990;52:1119-36
45. Kubo Y, Urano Y, Fukuhara K, et al. Lack of mutation in the INK4a locus in basal cell carcinomas. Br J Dermatol 1998;139:40-341
46. Gibbons RJ. Histone modifying and chromatin remodelling enzymes in cancer and dysplastic syndromes. Hum Mol Genet 2005;14:R85-92
47. Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 2005;23:3971-93
48. Esteller M. The necessity of a human epigenome project. Carcinogenesis 2006;276:1121-5
49. Cartei G, Cartei F, Interlandi G, et al. Oral 5-fluorouracil in squamous cell carcinoma of the skin in the aged. Am J Clin Oncol 2000;23:181-4
50. Cranmer LD, Engelhardt C, Morgan SS. Treatment of unresectable and metastatic cutaneous squamous cell carcinoma. Oncologist 2010;15:1320-8
51. Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 2005;23:3971-93
52. Dziunycz P, Iotzova-Weiss G, Eloranta JJ, et al. Squamous cell carcinoma of the skin shows a distinct microRNA profile modulated by UV radiation. J Investigat Dermatol 2010;130:2686-9
53. Sadek H, Azli N, Wendling JL, et al. Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin. Cancer 1990;66:1692-6
54. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14
55. Fujisawa Y, Umebayashi Y, Ichikawa E, et al. Chemoradiation using low-dose cisplatin and 5-fluorouracil in locally advanced squamous cell carcinoma of the skin: A report of two cases. J Am Acad Dermatol 2006;55(5 Suppl):S81-5
56. Guthrie TH Jr, Mc Elveen LJ, Porubsky ES, Harmon JD. Cisplatin and doxorubicin. An effective chemotherapy combination in the treatment of advanced basal cell and squamous carcinoma of the skin. Cancer 1985;55:1629-32
57. Wollina U, Hansel G, Koch A, Kostler E. Oral capecitabine plus subcutaneous interferon alpha in advanced squamous cell carcinoma of the skin. J Cancer Res Clin Oncol 2005;131:300-4
58. Shin DM, Glisson BS, Khuri FR, et al. Phase II and biologic study of inter-feron alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol 2002;20:364-70
59. Brewster AM, Lee JJ, Clayman GL, et al. Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. J Clin Oncol 2007;25:1974-8
60. Maubec E, Petrow P, Scheer-Senyarich I, et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 2011;29(25):3419-26
61. Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003;21:1980-7
62. Read W. Squamous carcinoma of the skin responding to erlotinib: Three cases. J Clin Oncol 2007;25(18 suppl):16519
63. Ribas A, Kim K, Schuchter L, et al. BRIM-2: An open-label, multicenter Phase II study of RG7204 (PLX4032) in previously treated patients with BRAF V600E mutation-positive metastatic melanoma [abstract]. J Clin Oncol 2011;29(Suppl):8509
64. Arnault JP, Wechsler J, Escudier B, et al. Kerato-acanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol 2009;27:e59-61
65. Caraglia M, Vitale G, Marra M, et al. Alpha-interferon and its effects on signaling pathways within the cells. Curr Protein Pept Sci 2004;5:475-85
66. Caraglia M, Marra M, Pelaia G, et al. Alpha-interferon and its effects on signal transduction pathways. J Cell Physiol 2005;202:323-35
67. You M, Yu DH, Feng GS. Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway. Mol Cell Biol 1999;19:2416-24
68. Bromberg J. Signal transducers and activators of transcription as regulators of growth, apoptosis and breast development. Breast Cancer Res 2000;2:86-90
69. Yang CH, Murti A, Pfeffer SR, et al. Interferon alpha/beta promotes cell survival by activating nuclear factor kappa B through phosphatidylinositol 3-kinase and Akt. J Biol Chem 2001;17:13756-61
70. Tagliaferri P, Caraglia M, Budillon A, et al. New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-alpha) treatment of human cancer. Cancer Immunol Immunother 2005;54:1-10
71. Caraglia M, Pinto A, Correale P, et al. 5-Aza-20-deoxycytidine induces growth inhibition and upregulation of epidermal growth factor receptor on human epithelial cancer cells. Ann Oncol 1994;5:269-76
72. Caraglia M, Tagliaferri P, Marra M, et al. EGF activates an inducible survival response via the RAS ^Erk-1/2 pathway to counteract interferon-a-mediated apoptosis in epidermoid cancer cells. Cell Death Differ 2003;10:218-29
73. Tagliaferri P, Caraglia M, Muraro R, et al. Pharmacological modulation of peptide growth factor receptor expression on tumour cells as a basis for cancer therapy. Anticancer Drugs 1994;5:379-93
74. Aikawa R, Komuro I, Yamazaki T, et al. Oxidative stress activates extracellular signal-regulated kinases through Src and Ras in cultured cardiac myocytes of neonatal rats. J Clin Invest 1997;100:1813-21
75. Lamberti A, Longo O, Marra M, et al. C-Raf antagonizes apoptosis induced by IFN-a in human lung cancer cells by phosphorylation and increase of the intracellular content of elongation factor 1A. Cell Death Differ 2007;14:952-62
76. Naviglio S, Spina A, Marra M, et al. Adenylate cyclase/cAMP pathway downmodulation counteracts apoptosis induced by IFN-alpha in human epidermoid cancer cells. J Interferon Cytokine Res 2007;27:129-36
77. Boccellino M, Giuberti G, Quagliuolo L, et al. Apoptosis Induced by Interferon-a and Antagonized by EGF Is Regulated by Caspase-3-Mediated Cleavage of Gelsolin in Human Epidermoid Cancer Cells. J Cell Physiol 2004;201:71-83
78. Budillon A, Di Gennaro E, Caraglia M, et al. 8-Cl-cAMP antagonizes mitogen-activated protein kinase activation and cell growth stimulation induced by epidermal growth factor. Br J Cancer 1999;81:1134-41
79. Lo Piccolo J, Granville CA, Gills JJ, Dennis PA. Targeting Akt in cancer therapy. Anticancer Drugs 2007;18:861-74
80. Milano A, Iaffaioli RV, Caponigro F. The proteasome: A worthwhile target for the treatment of solid tumours? Eur J Cancer 2007;43:1125-33
81. Cilloni D, Martinelli G, Messa F, et al. Nuclear factor kB as a target for new drug development in myeloid malignancies. Haematologica 2007;92:1124-229
82. Bruzzese F, Di Gennaro E, Avallone A, et al. Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo. Clin Cancer Res 2006;12:617-25
83. Caraglia M, Marra M, Viscomi C, et al. The farnesyltransferase inhibitor R115777 (ZARNESTRA) enhances the pro-apoptotic activity of interferon-a through the inhibition of multiple survival pathways. Int J Cancer 2007;121:2317-30
84. White E. Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer 2012; Epub ahead of print
85. Wang D, Boerner SA, Winkler JD, LoRusso PM. Clinical experience of MEK inhibitors in cancer therapy. Biochim Biophys Acta 2007;1773:1248-55
86. Caraglia M, Leardi A, Corradino S, et al. Alpha-Interferon potentiates epidermal growth factor receptor-mediated effects on human epidermoid carcinoma KB cells. Int J Cancer 1995;61:342-7
87. Caraglia M, Abbruzzese A, Leardi A, et al. Interferon-alpha induces apoptosis in human KB cells through a stress-dependent mitogen activated protein kinase pathway that is antagonized by epidermal growth factor. Cell Death Differ 1999;6:773-80
88. Esposito C, Marra M, Giuberti G, et al. Ubiquitination of tissue transglutaminase is modulated by interferon alpha in human lung cancer cells. Biochem J 2003;370:205-12
89. Caraglia M, Giuberti G, Marra M, et al. Docetaxel induces p53-dependent apoptosis and synergizes with farnesyl transferase inhibitor r115777 in human epithelial cancer cells. Front Biosci 2005;10:2566-75
90. Misso G, Giuberti G, Lombardi A, et al. Pharmacological inhibition of HSP90 and ras activity as a new strategy in the treatment of HNSCC. J Cell Physiol 2012; Epub ahead of print
91. Sung ES, Park KJ, Choi HJ, et al. The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells. Exp Cell Res 2012;318:1564-76
92. Fang L, Wang H, Zhou L, Yu D. FOXO3a reactivation mediates the synergistic cytotoxic effects of rapamycin and cisplatin in oral squamous cell carcinoma cells. Toxicol Appl Pharmacol 2011;251:8-15
93. Claerhout S, Verschooten L, Van Kelst S, et al. Concomitant inhibition of AKT and autophagy is required for efficient cisplatin-induced apoptosis of metastatic skin carcinoma. Int J Cancer 2010;127:2790-803
94. Bliesath J, Huser N, Omori M, et al. Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells. Cancer Lett 2012;322:113-18
95. Budillon A, Bruzzese F, Di Gennaro E, Caraglia M. Multiple-target drugs: Inhibitors of heat shock protein 90 and of histone deacetylase. Curr Drug Targets 2005;6(3):337-51
96. Oh SH, Whang YM, Min HY, et al. Histone deacetylase inhibitors enhance the apoptotic activity of insulin-like growth factor binding protein-3 by blocking PKC-induced IGFBP-3 degradation. Int J Cancer 2012; [Epub ahead of print]
97. Bruzzese F, Leone A, Rocco M, et al. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. J Cell Physiol 2011;226(9):2378-90
98. Bai LY, Chiu CF, Pan SL, et al. Antitumor activity of a novel histone deacetylase inhibitor (S)-HDAC42 in oral squamous cell carcinoma. Oral Oncol 2011;47(12):1127-33
99. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435:677-8
100. Li R, Zang Y, Li C, et al. ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway. Mol Pharmacol 2009;75:1231-9